Over the past decade, deaths from kidney, liver and some other cancers have risen. And Brexit has had an adverse impact on the development of new treatments, with researchers facing a trickier environment for clinical trials. One report last year pointed to the increased difficulty of international collaboration, reduced access to grant funding and border controls hindering the ability of experts to move around.